Evaluation of the efficacy of serial pancreatic-juice aspiration cytologic examination (SPACE) for pancreatic carcinoma in situ

Evaluation of the efficacy of serial pancreatic-juice aspiration cytologic examination (SPACE) for pancreatic carcinoma in situ - Evaluation of the efficacy of serial pancreatic-juice aspiration cytologic examination (SPACE)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039298

Enrollment

Registered

2020-01-29

Start date

2020-01-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic carcinoma in situ

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The pancreatic duct dilation, pancreatic duct stenosis, focal pancreatic atrophy and fatty change either CT, MRI or EUS. 2) Written informed consent.

Exclusion criteria

Exclusion criteria: 1)Unachievable ERCP due to difficult cannulation. 2)Unachievable ERCP due to post-abdominal surgery state including gastrectomy. 3)Inappropriate patients for study.

Design outcomes

Primary

Measure	Time frame
The accuracy of pancreatic juice cytology.	—

Secondary

Measure	Time frame
The evaluation of the image findings suggesting the pancreatic carcinoma in situ.	—

Countries

Japan

Contacts

Public ContactSawako Kuruma

Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital Department of Gastroenterology

sawako@cick.jp03-3823-2101

Outcome results